CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD22/CD19 CAR-T and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL — Stella

Recruiting

Back to B-cell Acute Lymphoblastic Leukemia trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu

Key details

Phase

Safety & dosing

Sponsor

The First Affiliated Hospital of Soochow University

Collaborators

National Natural Science Foundation of China, Jiangsu Province Natural Science Foundation of China (Grant No. BK20210091)

Enrollment target

~37 participants

Started

January 2020

Primary completion

July 2026

Age range

15 Years – 65 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov